Square Pharmaceuticals has signed agreements with two pharmaceuticals companies for manufacturing some products on behalf of the company to meet the growing demand.
“The board of Square Pharma has approved agreements with M/s Renata Oncology Ltd. and M/s Apex Pharma Ltd. for contract manufacturing of some products on behalf of the company to meet increased demand of existing products and to introduce new products,” said an official disclosure on Tuesday.
Recently, the Square Phrama also awarded with the good manufacturing practices certificate by the Congo.
The Square Pharma received the certificate, joining a growing list of medicine exporters from Bangladesh looking to make inroads into the African continent.
Each share of the Square Pharma, which was listed on the Dhaka bourse in 1995, closed at Tk 172.50 on Monday.
The company’s consolidated earnings per share (EPS) in six months for July-December 2019 was Tk 8.16 as against Tk 7.46 for July-December 2018.
The company disbursed 42 per cent cash and 7.0 per cent stock dividend for the year ended on June 30, 2019.
The company’s paid-up capital is Tk 8.44 billion and authorised capital is Tk 10 billion while total number of securities is 844.23 million.
The sponsor-director own 34.57 per cent stake in the company, while the institutional investors own 10.30 per cent, foreign investors 19.48 per cent and the general public 35.65 per cent as on February 29, 2020, the DSE data showed.
